Immunity to varicella zoster virus among pregnant women in the Norwegian Mother and Child Cohort Study

• Published in: PloS one Vol. 14; no. 8; p. e0221084
• Main Authors: Mirinaviciute, Grazina, Barlinn, Regine, Gjeruldsen Dudman, Susanne, Flem, Elmira
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 13.08.2019; PLOS; Public Library of Science (PLoS)
• Subjects: Adult; Age; Antibodies; Antibodies, Viral - immunology; Biology and life sciences; Birth; Chicken pox; Chickenpox; Chickenpox - epidemiology; Chickenpox - immunology; Childbirth & labor; Children; Chronology; Cohort analysis; Congenital diseases; Cross-Sectional Studies; Demographic aspects; Disease control; Disease susceptibility; Environmental health; Enzyme immunoassay; Enzymes; Epidemiology; Exposure; Female; Fever; Gestational age; Herpes zoster; Herpesvirus 3, Human - immunology; Humans; Immunity; Immunity (Physiology); Immunoassay; Immunoglobulin G; Immunoglobulin G - immunology; Infection; Infections; Infectious diseases; Medical examination; Medicine and Health Sciences; Middle Aged; Newborn infants; Norway - epidemiology; Obstetrics; Pediatric diseases; People and Places; Population; Pregnancy; Pregnancy Complications, Infectious - immunology; Pregnant women; Public health; Rash; Registries; Screening; Seroepidemiologic Studies; Serology; Target recognition; Testing; Vaccination; Vaccines; Varicella; Varicella-zoster virus; Virology; Viruses; Womens health; Young Adult; Norway; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0221084

Infection with varicella zoster virus (VZV) in pregnancy may lead to serious outcomes both for the mother and the newborn. Targeted screening and vaccination of non-immune women during reproductive age could prevent varicella infection in pregnancy. Currently, no universal varicella screening of pregnant women is implemented in Norway, but serological testing in pregnancy is recommended in particular situations. We examined seroprevalence of VZV in a national pregnancy cohort in order to help assess a need for VZV screening of women during reproductive age. We determined the susceptibility to VZV and the reliability of self-reported history of VZV infection in the Norwegian obstetric population by using a random sample of 1,184 pregnant women from the Norwegian Mother and Child Cohort study (MoBa). The MoBa study included approximately 95,200 pregnant women in Norway between 1998 and 2009. Blood samples taken at gestational week 17-18 were analysed using a commercial enzyme immunoassay for specific IgG antibodies to Varicella-Zoster virus. Second sample taken at birth was tested if the first sample result was negative or equivocal. Of the 1,184 pregnant women, 98.6% (n = 1,167) were seropositive, 0.83% (n = 10) remained seronegative, and four women (0.34%) seroconverted during their pregnancy. No significant associations were found between serological status and women's age at birth, gestational age, women's country of birth and year of child's birth. One woman reported prior history of varicella, whereas 143 (12.1%) women reported a household exposure to childhood diseases with fever and rash, of which 25 reported exposure to varicella, of which all were seropositive. The findings support antenatal screening recommendations in Norway advising testing for VZV in pregnant women with unknown immunity to VZV. Further studies are however needed to better identify target groups for screening and vaccination.